These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25004823)

  • 21. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles.
    Matera MG; Calzetta L; Rogliani P; Cazzola M
    Respir Med; 2019 Jul; 153():3-13. PubMed ID: 31136930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
    Hardiansyah D; Ng CM
    Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting the Effects of Anti-FcRn Therapy on the Disposition of Endogenous IgG in Humans.
    Li T; Balthasar JP
    J Pharm Sci; 2019 Jan; 108(1):714-724. PubMed ID: 30471293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data.
    Jones HM; Zhang Z; Jasper P; Luo H; Avery LB; King LE; Neubert H; Barton HA; Betts AM; Webster R
    CPT Pharmacometrics Syst Pharmacol; 2019 Oct; 8(10):738-747. PubMed ID: 31464379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human FcRn Tissue Expression Profile and Half-Life in PBMCs.
    Fan YY; Farrokhi V; Caiazzo T; Wang M; O'Hara DM; Neubert H
    Biomolecules; 2019 Aug; 9(8):. PubMed ID: 31443181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic models for FcRn-mediated IgG disposition.
    Xiao JJ
    J Biomed Biotechnol; 2012; 2012():282989. PubMed ID: 22665983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.
    Hardiansyah D; Ng CM
    Pharm Res; 2018 Feb; 35(3):47. PubMed ID: 29411151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
    Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
    MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance.
    Goulet DR; Watson MJ; Tam SH; Zwolak A; Chiu ML; Atkins WM; Nath A
    Drug Metab Dispos; 2018 Dec; 46(12):1900-1907. PubMed ID: 30232177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of altered endogenous IgG on unspecific mAb clearance.
    Fuhrmann S; Kloft C; Huisinga W
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improvement of pharmacokinetic properties of therapeutic antibodies by antibody engineering.
    Haraya K; Tachibana T; Igawa T
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):25-41. PubMed ID: 30472066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism-Based Competitive Binding Model to Investigate the Effect of Neonatal Fc Receptor Binding Affinity on the Pharmacokinetic of Humanized Anti-VEGF Monoclonal IgG1 Antibody in Cynomolgus Monkey.
    Ng CM; Fielder PJ; Jin J; Deng R
    AAPS J; 2016 Jul; 18(4):948-59. PubMed ID: 27075465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies.
    Wang W; Vlasak J; Li Y; Pristatsky P; Fang Y; Pittman T; Roman J; Wang Y; Prueksaritanont T; Ionescu R
    Mol Immunol; 2011 Mar; 48(6-7):860-6. PubMed ID: 21256596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
    Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
    Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IgG1 Allotypes Influence the Pharmacokinetics of Therapeutic Monoclonal Antibodies through FcRn Binding.
    Ternant D; Arnoult C; Pugnière M; Dhommée C; Drocourt D; Perouzel E; Passot C; Baroukh N; Mulleman D; Tiraby G; Watier H; Paintaud G; Gouilleux-Gruart V
    J Immunol; 2016 Jan; 196(2):607-13. PubMed ID: 26685205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).
    Dall'Acqua WF; Kiener PA; Wu H
    J Biol Chem; 2006 Aug; 281(33):23514-24. PubMed ID: 16793771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.